TY - JOUR AU - Smeenk, R. M. AU - Velthuysen, M. L. AU - Verwaal, V. J. PY - 2008 DA - 2008// TI - Appendiceal neoplasms and pseudomyxoma peritonei: a population based study JO - Eur J Surg Oncol VL - 34 UR - https://doi.org/10.1016/j.ejso.2007.04.002 DO - 10.1016/j.ejso.2007.04.002 ID - Smeenk2008 ER - TY - BOOK AU - Bosman, F. T. AU - Carneiro, F. AU - Hruban, R. H. PY - 2010 DA - 2010// TI - WHO classification of tumours of the digestive system PB - International Agency for Research on Cancer CY - Lyon, France ID - Bosman2010 ER - TY - JOUR AU - Bradley, R. F. AU - Stewart, J. H. AU - Russell, G. B. PY - 2006 DA - 2006// TI - Pseudomyxoma peritonei of appendiceal origin: a clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review JO - Am J Surg Pathol VL - 30 UR - https://doi.org/10.1097/01.pas.0000202039.74837.7d DO - 10.1097/01.pas.0000202039.74837.7d ID - Bradley2006 ER - TY - JOUR AU - Austin, F. AU - Mavanur, A. AU - Sathaiah, M. PY - 2012 DA - 2012// TI - Aggressive management of peritoneal carcinomatosis from mucinous appendiceal neoplasms JO - Ann Surg Oncol VL - 19 UR - https://doi.org/10.1245/s10434-012-2241-6 DO - 10.1245/s10434-012-2241-6 ID - Austin2012 ER - TY - JOUR AU - Sugarbaker, P. H. PY - 2006 DA - 2006// TI - New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? JO - Lancet Oncol VL - 7 UR - https://doi.org/10.1016/S1470-2045(05)70539-8 DO - 10.1016/S1470-2045(05)70539-8 ID - Sugarbaker2006 ER - TY - JOUR AU - Pietrantonio, F. AU - Maggi, C. AU - Fanetti, G. PY - 2014 DA - 2014// TI - FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma JO - Oncologist VL - 19 UR - https://doi.org/10.1634/theoncologist.2014-0106 DO - 10.1634/theoncologist.2014-0106 ID - Pietrantonio2014 ER - TY - JOUR AU - Farquharson, A. L. AU - Pranesh, N. AU - Witham, G. PY - 2008 DA - 2008// TI - A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei JO - Br J Cancer VL - 99 UR - https://doi.org/10.1038/sj.bjc.6604522 DO - 10.1038/sj.bjc.6604522 ID - Farquharson2008 ER - TY - JOUR AU - Cremolini, C. AU - Schirripa, M. AU - Antoniotti, C. PY - 2015 DA - 2015// TI - First-line chemotherapy for mCRC-a review and evidence-based algorithm JO - Nat Rev Clin Oncol VL - 10 UR - https://doi.org/10.1038/nrclinonc.2015.129 DO - 10.1038/nrclinonc.2015.129 ID - Cremolini2015 ER - TY - JOUR AU - Burger, R. A. AU - Sill, M. W. AU - Monk, B. J. PY - 2007 DA - 2007// TI - Phase II trial of Bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a gynecologic oncology group study JO - J Clin Oncol VL - 25 UR - https://doi.org/10.1200/JCO.2007.11.5345 DO - 10.1200/JCO.2007.11.5345 ID - Burger2007 ER - TY - JOUR AU - Garcia, A. A. AU - Hirte, H. AU - Fleming, G. PY - 2008 DA - 2008// TI - Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago and Princess Margaret Hospital phase II consortia JO - J Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2007.12.1939 DO - 10.1200/JCO.2007.12.1939 ID - Garcia2008 ER - TY - JOUR AU - Pietrantonio, F. AU - Biondani, P. AU - Pellegrinelli, A. PY - 2012 DA - 2012// TI - Hepatic colorectal cancer metastases showing a distinctive pattern of pathological response after metronomic capecitabine and bevacizumab JO - Med Oncol VL - 29 UR - https://doi.org/10.1007/s12032-011-0132-5 DO - 10.1007/s12032-011-0132-5 ID - Pietrantonio2012 ER - TY - JOUR AU - Eisenhauer, E. A. AU - Therasse, P. AU - Bogaerts, J. PY - 2009 DA - 2009// TI - New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) JO - Eur J Cancer VL - 45 UR - https://doi.org/10.1016/j.ejca.2008.10.026 DO - 10.1016/j.ejca.2008.10.026 ID - Eisenhauer2009 ER - TY - STD TI - NCI CTEP. Common Terminology Criteria for Adverse Events (CTCAE)v4.0. 2010. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/About.html. ID - ref13 ER - TY - JOUR AU - McLaren, W. AU - Pritchard, B. AU - Rios, D. PY - 2010 DA - 2010// TI - Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor JO - Bioinformatics VL - 26 UR - https://doi.org/10.1093/bioinformatics/btq330 DO - 10.1093/bioinformatics/btq330 ID - McLaren2010 ER - TY - JOUR AU - Pietrantonio, F. AU - Perrone, F. AU - Braud, F. PY - 2014 DA - 2014// TI - Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation JO - Ann Oncol VL - 25 UR - https://doi.org/10.1093/annonc/mdt547 DO - 10.1093/annonc/mdt547 ID - Pietrantonio2014 ER - TY - JOUR AU - Samamé Pérez-Vargas, J. C. AU - Biondani, P. AU - Maggi, C. PY - 2013 DA - 2013// TI - Role of cMET in the development and progression of colorectal cancer JO - Int J Mol Sci VL - 14 UR - https://doi.org/10.3390/ijms140918056 DO - 10.3390/ijms140918056 ID - Samamé Pérez-Vargas2013 ER - TY - JOUR AU - Normanno, N. AU - Rachiglio, A. M. AU - Lambiase, M. PY - 2015 DA - 2015// TI - Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial JO - Ann Oncol VL - 26 UR - https://doi.org/10.1093/annonc/mdv176 DO - 10.1093/annonc/mdv176 ID - Normanno2015 ER - TY - JOUR AU - Shapiro, J. F. AU - Chase, J. L. AU - Wolff, R. A. PY - 2010 DA - 2010// TI - Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin: a single-institution experience JO - Cancer VL - 116 UR - https://doi.org/10.1002/cncr.24715 DO - 10.1002/cncr.24715 ID - Shapiro2010 ER - TY - JOUR AU - Levitz, J. S. AU - Sugarbaker, P. H. AU - Lichtman, S. M. PY - 2004 DA - 2004// TI - Unusual abdominal tumors, case 1. Pseudomyxoma peritonei: response to capecitabine JO - J Clin Oncol VL - 22 UR - https://doi.org/10.1200/JCO.2004.05.126 DO - 10.1200/JCO.2004.05.126 ID - Levitz2004 ER - TY - JOUR AU - Kerbel, R. S. AU - Kamen, B. A. PY - 2004 DA - 2004// TI - The anti-angiogenic basis of metronomic chemotherapy JO - Nat Rev Cancer VL - 4 UR - https://doi.org/10.1038/nrc1369 DO - 10.1038/nrc1369 ID - Kerbel2004 ER - TY - JOUR AU - Gasparini, G. PY - 2001 DA - 2001// TI - Metronomic scheduling: the future of chemotherapy? JO - Lancet Oncol VL - 2 UR - https://doi.org/10.1016/S1470-2045(01)00587-3 DO - 10.1016/S1470-2045(01)00587-3 ID - Gasparini2001 ER - TY - JOUR AU - Pasquier, E. AU - Kavallaris, M. AU - Andre´, N. PY - 2010 DA - 2010// TI - Metronomic chemotherapy: new rationale for new directions JO - Nat Rev Clin Oncol VL - 7 UR - https://doi.org/10.1038/nrclinonc.2010.82 DO - 10.1038/nrclinonc.2010.82 ID - Pasquier2010 ER - TY - JOUR AU - Hanahan, D. AU - Bergers, G. AU - Bergsland, E. PY - 2000 DA - 2000// TI - Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice JO - J Clin Invest VL - 105 UR - https://doi.org/10.1172/JCI9872 DO - 10.1172/JCI9872 ID - Hanahan2000 ER - TY - JOUR AU - Sun, W. L. AU - Hutarew, G. AU - Gradl, J. PY - 2009 DA - 2009// TI - Successful antiangiogenic combination therapy for pseudomyxoma peritonei with bevacizumab and capecitabine JO - Cancer Biol Ther VL - 8 UR - https://doi.org/10.4161/cbt.8.15.8943 DO - 10.4161/cbt.8.15.8943 ID - Sun2009 ER - TY - JOUR AU - Raghav, K. P. AU - Shetty, A. V. AU - Kazmi, S. M. PY - 2013 DA - 2013// TI - Impact of molecular alterations and targeted therapy in appendiceal adenocarcinomas JO - Oncologist VL - 18 UR - https://doi.org/10.1634/theoncologist.2013-0186 DO - 10.1634/theoncologist.2013-0186 ID - Raghav2013 ER - TY - JOUR AU - Chua, T. C. AU - Moran, B. J. AU - Sugarbaker, P. H. PY - 2012 DA - 2012// TI - Early and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy JO - J Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2011.39.7166 DO - 10.1200/JCO.2011.39.7166 ID - Chua2012 ER - TY - JOUR AU - Baratti, D. AU - Kusamura, S. AU - Nonaka, D. PY - 2009 DA - 2009// TI - Pseudomyxoma peritonei: biological features are the dominant prognostic determinants after complete cytoreduction and hyperthermic intraperitoneal chemotherapy JO - Ann Surg VL - 249 UR - https://doi.org/10.1097/SLA.0b013e31818eec64 DO - 10.1097/SLA.0b013e31818eec64 ID - Baratti2009 ER - TY - JOUR AU - Nummela, P. AU - Saarinen, L. AU - Thiel, A. PY - 2015 DA - 2015// TI - Genomic profile of pseudomyxoma peritonei analyzed using next-generation sequencing and immunohistochemistry JO - Int J Cancer VL - 136 UR - https://doi.org/10.1002/ijc.29245 DO - 10.1002/ijc.29245 ID - Nummela2015 ER - TY - JOUR AU - Nishikawa, G. AU - Sekine, S. AU - Ogawa, R. PY - 2013 DA - 2013// TI - Frequent GNAS mutations in low-grade appendiceal mucinous neoplasms JO - Br J Cancer VL - 108 UR - https://doi.org/10.1038/bjc.2013.47 DO - 10.1038/bjc.2013.47 ID - Nishikawa2013 ER - TY - JOUR AU - Fecteau, R. E. AU - Lutterbaugh, J. AU - Markowitz, S. D. PY - 2014 DA - 2014// TI - GNAS mutations identify a set of right-sided, RAS mutant, villous colon cancers JO - PLoS One VL - 9 UR - https://doi.org/10.1371/journal.pone.0087966 DO - 10.1371/journal.pone.0087966 ID - Fecteau2014 ER - TY - JOUR AU - Austin, F. AU - Manavur, A. AU - Sathaiah, M. PY - 2012 DA - 2012// TI - Aggressive management of peritoneal carcinomatosis from mucinous appendiceal neoplasm JO - Ann Surg Oncol VL - 19 UR - https://doi.org/10.1245/s10434-012-2241-6 DO - 10.1245/s10434-012-2241-6 ID - Austin2012 ER - TY - JOUR AU - Molinari, F. AU - Felicioni, L. AU - Buscarino, M. PY - 2011 DA - 2011// TI - Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer JO - Clin Cancer Res VL - 17 UR - https://doi.org/10.1158/1078-0432.CCR-10-3137 DO - 10.1158/1078-0432.CCR-10-3137 ID - Molinari2011 ER -